Magazine Article | September 1, 2023

Companies To Watch: Nido Biosciences

Source: Life Science Leader

By Wayne Koberstein, Executive Editor, Life Science Leader
Follow Me On Twitter @WayneKoberstein

Developing small molecule drugs for rare neurodegenerative diseases

Nido Biosciences is in early clinical and preclinical development of small molecule drugs targeting neurodegenerative disorders with a variety of disease mechanisms. Its lead pipeline drug, coded NIDO-361, is in a Phase 1 trial for treatment of spinal and bulbar muscular atrophy (SBMA). Additional preclinical drug candidates will aim at ALS (amyotrophic lateral sclerosis), rare tauopathies, frontotemporal dementia (FTD), and other indications.

access the Magazine Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Life Science Leader? Subscribe today.

Subscribe to Life Science Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Life Science Leader